UCB Japan Becomes Platinum Sponsor for the 160th Anniversary of Belgium-Japan Relations

UCB Japan Co., Ltd. (Headquarters: Shinjuku-ku, Tokyo; President: Kanako Kikuchi) is pleased to announce its role as a platinum sponsor for the projects commemorating the 160th anniversary of friendship between Belgium and Japan. As a company with its global headquarters in Belgium, we pay tribute to the historical ties built between the two nations and look forward to contributing to the deepening of cultural and professional exchanges through these commemorative events.

Since the establishment of diplomatic relations in 1866, Belgium and Japan have fostered deep ties based on mutual understanding and trust, spanning culture, economy, science, and innovation. This 160th-anniversary project serves as an important opportunity to reflect on these 160 years of history, celebrate their value, and envision new possibilities for collaboration for future generations.

As the Japanese subsidiary of UCB, a global biopharma headquartered in Brussels, we have been operating in Japan since 1988. We have contributed to the improvement of patients' quality of life (QOL) by developing pharmaceutical businesses in areas such as epilepsy, rheumatoid arthritis, psoriasis, and rare diseases.

President Kanako Kikuchi stated, "It is a great honor for UCB Japan to participate as a platinum sponsor for these commemorative projects during this milestone of deep trust and friendship. With over 90 years of history in Belgium, UCB has been committed to expanding treatment options while walking alongside the Japanese medical community and society. We remain focused on creating a better future through innovation that meets the unmet needs of patients while cherishing cross-border partnerships."

Through these commemorative projects, UCB Japan plans to host various internal and external events on topics such as medicine, culture, and women's leadership to further deepen mutual understanding and cooperation.

For more details, please visit the special website of the Embassy of Belgium in Japan for the 160th Anniversary of Belgium-Japan relations: https://belgiumjapan160.jp/.

About UCB

UCB (www.ucb.com) is a global biopharmaceutical company headquartered in Brussels, Belgium, focused on creating innovative medicines and solutions for people living with severe diseases in neurology and immunology. The company operates in nearly 40 countries, employs over 10,000 people, and recorded revenue of 7.7 billion Euros in 2025. UCB is listed on the Euronext Brussels stock exchange.

UCB Japan was established in 1988 as the Japanese subsidiary of UCB, focusing primarily on treatments for epilepsy, rheumatoid arthritis, and psoriasis. Since 2023, the company has also expanded into the rare disease sector. As a leader in creating value for patients, UCB Japan aims to provide new treatment choices for patients who have not achieved sufficient improvement with traditional therapies.